MENU
+Compare
ABCL
Stock ticker: NASDAQ
AS OF
Apr 2 closing price
Price
$2.22
Change
+$0.13 (+6.22%)
Capitalization
661.53M

ABCL AbCellera Biologics Forecast, Technical & Fundamental Analysis

AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner... Show more

ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ABCL with price predictions
Apr 02, 2025

ABCL's RSI Oscillator ascending out of oversold territory

The RSI Indicator for ABCL moved out of oversold territory on April 02, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in of 193 cases, the price rose further within the following month. The odds of a continued upward trend are .

ABCL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ABCL as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on April 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for ABCL crossed bearishly below the 50-day moving average on February 28, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for ABCL moved below the 200-day moving average on April 02, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ABCL entered a downward trend on March 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.626) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (22.676) is also within normal values, averaging (252.036).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ABCL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ABCL is expected to report earnings to rise 5.58% to -12 cents per share on May 13

AbCellera Biologics ABCL Stock Earnings Reports
Q1'25
Est.
$-0.13
Q4'24
Beat
by $0.01
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.01
Q1'24
Missed
by $0.02
The last earnings report on February 27 showed earnings per share of -11 cents, beating the estimate of -12 cents. With 4.07M shares outstanding, the current market capitalization sits at 661.53M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2215 Yukon Street
Phone
+1 604 559-9005
Employees
586
Web
https://www.abcellera.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSCCX15.64N/A
N/A
JHancock Small Cap Value R6
FIDZX32.91N/A
N/A
Fidelity Advisor Intl Cap App Z
FARLX10.80N/A
N/A
FS Chiron Real Development A
JIJIX13.38N/A
N/A
JHancock International Dynamic Gr I
PWITX17.78N/A
N/A
PACE International Equity Invmt P2

ABCL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with CRSP. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+6.22%
CRSP - ABCL
58%
Loosely correlated
+3.17%
NTLA - ABCL
56%
Loosely correlated
+9.69%
VCYT - ABCL
56%
Loosely correlated
+1.93%
BEAM - ABCL
55%
Loosely correlated
+4.79%
ABSI - ABCL
53%
Loosely correlated
+3.33%
More